The health company Nyxoah will issue an additional 650,250 new shares on Tuesday. The company will thus be able to collect an additional 11.05 million euros in gross product. Nyxoah has developed technology for sleep apnea and related snoring.
An “over-allotment option” to subscribe 650,250 additional new shares at the final issue price of 17 euros per share has been granted. The option was exercisable for a period of 30 calendar days from the first day of admission of the shares to trading on the regulated market of Euronext Brussels (ie September 18).
The total gross proceeds raised under the offering are € 84.7 million ($ 100 million). The Walloon company intends to carry out clinical tests in the United States, Europe and Australia for the development of new products.